DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DMAC DiaMedica Therapeutics Inc.

Market Closed 04-11 16:00:00 EDT

3.47

-0.04

-1.14%

盘后3.47

+0.000.00%

16:05 EDT

High3.60	Low3.45	Vol50.75K
Open3.52	D1 Closing3.51	Amplitude4.27%
Mkt Cap148.71M	Tradable Cap83.89M	Total Shares42.86M
T/O178.25K	T/O Rate0.21%	Tradable Shares24.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"DMAC","market":"US","secType":"STK","nameCN":"DiaMedica Therapeutics Inc.","latestPrice":3.47,"timestamp":1744401600000,"preClose":3.51,"halted":0,"volume":50751,"hourTrading":{"tag":"盘后","latestPrice":3.47,"preClose":3.47,"latestTime":"16:05 EDT","volume":1,"amount":3.47,"timestamp":1744401911169},"delay":0,"floatShares":24175006,"shares":42855660,"eps":-0.604979,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-11 16:00:00 EDT","open":3.52,"high":3.6,"low":3.45,"amount":178247.3942,"amplitude":0.042735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.604979,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":3.51,"preHourTrading":{"tag":"盘前","latestPrice":3.52,"preClose":3.51,"latestTime":"09:29 EDT","volume":172,"amount":650.489982,"timestamp":1744378198423},"postHourTrading":{"tag":"盘后","latestPrice":3.47,"preClose":3.47,"latestTime":"16:05 EDT","volume":1,"amount":3.47,"timestamp":1744401911169},"volumeRatio":0.5631478844640168,"impliedVol":1.3766,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/DMAC","defaultTab":"news","newsList":[{"id":"2520187316","title":"Diamedica Therapeutics (DMAC) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2520187316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520187316?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 20:57","pubTimestamp":1742389044,"startTime":"0","endTime":"0","summary":"Lake Street analyst Thomas Flaten maintained a Buy rating on Diamedica Therapeutics (DMAC – Research Report) today and set a price target of $11.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/diamedica-therapeutics-dmac-gets-a-buy-from-lake-street?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/diamedica-therapeutics-dmac-gets-a-buy-from-lake-street?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2520778279","title":"DiaMedica Therapeutics Inc. : H.c. Wainwright Raises Target Price to $10 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2520778279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520778279?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:08","pubTimestamp":1742378917,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nAZN3KVEFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMAC"],"gpt_icon":0},{"id":"2520446269","title":"DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2520446269","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520446269?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 15:00","pubTimestamp":1742367659,"startTime":"0","endTime":"0","summary":"Cash and Investments: $44.1 million as of December 31, 2024.Net Cash Used in Operating Activities: $22.1 million for the full year 2024.Research and Development Expenses: $19.1 million for the year ended December 31, 2024.General and Administrative Expenses: $7.6 million for the full year 2024.Net Other Income: $2.3 million for the full year 2024.GuruFocus has detected 3 Warning Signs with DMAC.For the complete transcript of the earnings call, please refer to the full earnings call transcript.DiaMedica Therapeutics Inc  has made significant progress in its preeclampsia clinical program, obtaining ethics approval and beginning dosing in South Africa.The company's DM199 treatment shows promise due to its safety profile, ability to produce nitric oxide, and potential to lower blood pressure without crossing the placental barrier.The stroke program has activated 30 clinical sites, increasing the potential for steady enrollment and expanding the eligible patient population.Q: What are the e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamedica-therapeutics-inc-dmac-q4-070059166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DMAC"],"gpt_icon":0},{"id":"2520102995","title":"Q4 2024 DiaMedica Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520102995","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520102995?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 10:22","pubTimestamp":1742350975,"startTime":"0","endTime":"0","summary":"Rick Pauls; President, Chief Executive Officer, Director; DiaMedica Therapeutics Inc. Scott Kellen; Chief Financial Officer, Company Secretary; DiaMedica Therapeutics Inc. Thank you, operator. Hello, everyone, and welcome to our full year 2024 conference call. I'm joined this morning by Scott Kellen, our Chief Financial Officer, and Dr. Lorianne Masuoka, our Chief Medical Officer. We're happy to be here today to update you on the progress of our two main clinical development programs. Seeing that our next expected clinical milestone is for our preeclampsia study, I'll ask Lorianne to start with an update on our preeclampsia program, and then we'll turn to our stroke study.Thanks, Rick. Starting with preeclampsia, we are very pleased with our progress in this clinical program. Less than a year ago, our collaborators submitted the first draft of the protocol to the Tygerberg Hospital's ethics Board. Since then, we have obtained ethics approval, clearance from the South African Health Pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-diamedica-therapeutics-inc-022255580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","DMAC"],"gpt_icon":0},{"id":"2520968482","title":"DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520968482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520968482?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:44","pubTimestamp":1742247840,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryDiaMedica Therapeutics Inc DMAC.OQ reported a quarterly adjusted loss of 18 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL8N3Q01W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC"],"gpt_icon":0},{"id":"2520268373","title":"DiaMedica Therapeutics: Preeclampsia Phase 2 Trial Preliminary Topline Safety, Efficacy Data From Part 1a of Study Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520268373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520268373?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:31","pubTimestamp":1742243478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00TW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMAC"],"gpt_icon":0},{"id":"2520683405","title":"Press Release: DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520683405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520683405?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:30","pubTimestamp":1742243400,"startTime":"0","endTime":"0","summary":"Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time. -- Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data. from Part 1A of the Study Expected in the Second Quarter of 2025. -- Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing. -- Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board. DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2024 financial results.DiaMedica further reports that its data safety monitoring board  completed its scheduled safety review of the new intravenous dosing rates implemented upon resumption of the ReMEDy2 trial. Based upon that r","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","LENZ","DMAC","BK4561","AIS","BK4006","TNK","MT","BK4139","BK4144"],"gpt_icon":0},{"id":"2520528102","title":"Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2520528102","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520528102?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:44","pubTimestamp":1742211892,"startTime":"0","endTime":"0","summary":"Over the last year, a good number of insiders have significantly increased their holdings in DiaMedica Therapeutics Inc. . This is encouraging because it indicates that insiders are more optimistic about the company's prospects.While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.The Last 12 Months Of Insider Transactions At DiaMedica Therapeutics. Over the last year, we can see that the biggest insider purchase was by insider Jan Stahlberg for US$3.0m worth of shares, at about US$2.50 per share. We do like to see buying, but this purchase was made at well below the current price of US$5.77. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-stock-buying-reaches-us-114452490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","DMAC"],"gpt_icon":0},{"id":"2520889517","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520889517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520889517?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","ABSI","FIVE","CNTX","STNE","BLTE","CAL","DMAC","IMTX","RWAY","NRXP","SPRY","PHUN","CELC","ASO","RBOT","STTK","GLUE","SAIC","OPTN","SCPH","HYPR","BTM","AEVA","CBUS","DERM","ANRO","KOPN","SGMO","AUTL","MSIF","PL","OABI","KLC","DRI","LVTX","OSS","FLUX","LPRO","LQDA","LXEO","NOA","INO","LEN.B","BCAB","SIG","RANI","LAR"],"gpt_icon":1},{"id":"2519332072","title":"DiaMedica Therapeutics Inc  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519332072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519332072?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 04:28","pubTimestamp":1741984086,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc  expected to post a loss of17cents a share - Earnings Preview DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to show no change in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX23Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC"],"gpt_icon":0},{"id":"2518743232","title":"Press Release: DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518743232?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:23","pubTimestamp":1741695780,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025. DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17 . DiaMedica will host a live conference call on Tuesday, March 18 at 7:00 AM Central Time to provide a business update and discuss financial results.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC","LENZ"],"gpt_icon":0},{"id":"2518176440","title":"Insiders At DiaMedica Therapeutics See Good Returns After Buying Stock Worth US$9.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2518176440","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518176440?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 21:58","pubTimestamp":1741442328,"startTime":"0","endTime":"0","summary":"Insiders who purchased DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) shares in the past 12 months are unlikely to be...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/insiders-at-diamedica-therapeutics-see-good-returns-after-bu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","DMAC","BK4139"],"gpt_icon":0},{"id":"2513729188","title":"DiaMedica Therapeutics Appoints Daniel J. O’connor to the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729188","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729188?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA8LVHLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2513290157","title":"DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2513290157","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513290157?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, February 24, 2025----DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025.Mr. O’Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. , ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet . Mr. O’Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, where under his leadership the company grew from a $40 million valuation upon him joining the company to being acquired by Johnson & Johnson for $2 billion just 14 months later. His expertise spans across capital markets, licensing transactions, business development, corporate strategy, clinical development and reg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamedica-therapeutics-appoints-daniel-j-133000201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DMAC","AIS","LENZ"],"gpt_icon":0},{"id":"2510698813","title":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2510698813","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510698813?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 05:15","pubTimestamp":1739222100,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, February 10, 2025----DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time.Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Oppenheimer representative to arrange a meeting.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamedica-therapeutics-present-oppenheimer-35th-211500183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","DMAC","BK4139","BK4127","HCSG","OPY","LENZ"],"gpt_icon":0},{"id":"2495559135","title":"Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$43m","url":"https://stock-news.laohu8.com/highlight/detail?id=2495559135","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495559135?lang=en_us&edition=full_marsco","pubTime":"2024-12-29 20:42","pubTimestamp":1735476140,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in DiaMedica Therapeutics indicates that they...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/individual-investors-are-diamedica-therapeutics-incs-nasdaqd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","TSYW.SI","BK4112","NQmain","QID","SQQQ","NDAQ",".IXIC","DMAC","NVIW.SI","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","BK4139","QLD","USJW.SI","MNQmain","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","TQQQ","USAW.SI","IE00BGHQF748.EUR","BK4585","PSQ"],"gpt_icon":1},{"id":"2492574126","title":"Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m","url":"https://stock-news.laohu8.com/highlight/detail?id=2492574126","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492574126?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 19:34","pubTimestamp":1734608079,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in DiaMedica Therapeutics indicates that they collectively have a greater say in management and business strategy. 50% of the business is held by the top 8 shareholders. If you want to know who really controls DiaMedica Therapeutics Inc. , then you'll have to look at the makeup of its share registry. With 43% stake, individual investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .While the holdings of individual investors took a hit after last week’s 11% price drop, insiders with their 39% also suffered.While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the bo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/individual-investors-diamedica-therapeutics-inc-113439388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","LU2095319765.USD","SQQQ","DMAC","QLD","USAW.SI","USJW.SI","TSYW.SI","NQmain","IE00BKPKM429.USD","IE00B64PRP62.GBP","TQQQ","LU2210149790.SGD","LU2210150020.SGD","BK4112","BK4588","QID","NVIW.SI",".IXIC","BK4585","BK4139","IE00BGHQF748.EUR","NDAQ","PSQ","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2491940246","title":"Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491940246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491940246?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 22:31","pubTimestamp":1734359464,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Qiagen (QGEN – Research Report) and Diamedica Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-and-diamedica-therapeutics-dmac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-and-diamedica-therapeutics-dmac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1923622614.USD","LU2125909247.SGD","BK4121","BK4137","QGEN","BK4139","LU2433249047.HKD","DMAC","LU2125909593.SGD","HCSG"],"gpt_icon":0},{"id":"2488854917","title":"DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of Dm199 for the Treatment of Preeclampsia","url":"https://stock-news.laohu8.com/highlight/detail?id=2488854917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488854917?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 21:25","pubTimestamp":1733232300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUAHF1ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2488948458","title":"DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia","url":"https://stock-news.laohu8.com/highlight/detail?id=2488948458","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488948458?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 21:25","pubTimestamp":1733232300,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, December 03, 2024----DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific Advisory Board  to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia . The members of the newly formed SAB are renowned experts in PE and maternal-fetal health and will collaborate closely with the company’s leadership to accelerate the development of DM199, for the treatment of preeclampsia.\"We are thrilled to welcome these distinguished doctors to our Scientific Advisory Board,\" said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. \"Their expertise and guidance will be invaluable as we work to advance treatment options for this potentially fatal and life-threatening condition.\". Lorianne Masuoka, DiaMedica Therapeutics’ Chief Medical Officer added, \"The insights from ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R60koqjQhohmDxKHyezicw--~B/aD00MDA7dz0xODc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a2bd5ca029cd9c320bd3afb724efdb3f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R60koqjQhohmDxKHyezicw--~B/aD00MDA7dz0xODc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a2bd5ca029cd9c320bd3afb724efdb3f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamedica-therapeutics-announces-formation-scientific-132500239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","BK4139","LENZ","DMAC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.diamedica.com","stockEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.4017},{"period":"3month","weight":-0.3416},{"period":"6month","weight":-0.1835},{"period":"1year","weight":0.3661},{"period":"ytd","weight":-0.361}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.052477},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07616},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.098399},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.001515},{"month":5,"riseRate":0.666667,"avgChangeRate":0.110547},{"month":6,"riseRate":0.666667,"avgChangeRate":0.220348},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.150502},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002116},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.139813},{"month":10,"riseRate":0.5,"avgChangeRate":0.04107},{"month":11,"riseRate":0.833333,"avgChangeRate":0.123635},{"month":12,"riseRate":0.666667,"avgChangeRate":0.299947}],"exchange":"NASDAQ","name":"DiaMedica Therapeutics Inc.","nameEN":"DiaMedica Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DiaMedica Therapeutics Inc.,DMAC,DiaMedica Therapeutics Inc.股票,DiaMedica Therapeutics Inc.股票老虎,DiaMedica Therapeutics Inc.股票老虎国际,DiaMedica Therapeutics Inc.行情,DiaMedica Therapeutics Inc.股票行情,DiaMedica Therapeutics Inc.股价,DiaMedica Therapeutics Inc.股市,DiaMedica Therapeutics Inc.股票价格,DiaMedica Therapeutics Inc.股票交易,DiaMedica Therapeutics Inc.股票购买,DiaMedica Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}